SCHEMBL21035615

SCHEMBL21035615

NC1CC2CCC(C1)N2C(=O)[C@@H]1C[C@H](Nc2ccc(Cl)cc2)CN1S(=O)(=O)c1ccc2cc(OC3CCCC3)ccc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 2/20 0.38
HTR1A P08908 2/20 0.35
HTR7 P34969 2/20 0.35
HTR5A P47898 2/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
ADRA1A P35348 1/20 0.35
HTR2B P41595 1/20 0.35
HTR6 P50406 1/20 0.35
HTR4 Q13639 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
ITGB1 P05556 1/20 0.35
ITGA4 P13612 1/20 0.35
MMP9 P14780 3/20 0.34
MMP1 P03956 2/20 0.34
MMP3 P08254 2/20 0.34
ADAM17 P78536 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21035612 1.00 GHSR (0.38) GHSRHTR1AHTR7HTR5AHTR1D
SCHEMBL21035614 1.00 GHSR (0.38) GHSRHTR1AHTR7HTR5AHTR1D
SCHEMBL21035403 0.89 HTR1A (0.39) GHSRHTR1AHTR7HTR5AHTR1D
SCHEMBL21035319 0.89 HTR1A (0.39) GHSRHTR1AHTR7HTR5AHTR1D
SCHEMBL21035619 0.88 MMP9 (0.37) MMP9MMP1MMP3ADAM17MMP2
SCHEMBL21035618 0.86 CA12 (0.41) HTR1AHTR7HTR5AHTR1DHTR1B
SCHEMBL21034939 0.85 HTR1A (0.42) GHSRHTR1AHTR7HTR5AHTR1D
SCHEMBL21035665 0.85 HTR1A (0.42) GHSRHTR1AHTR7HTR5AHTR1D
SCHEMBL21034995 0.85 HTR1A (0.42) GHSRHTR1AHTR7HTR5AHTR1D
SCHEMBL21035133 0.84 HTR1A (0.41) GHSRHTR1AHTR7HTR5AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed